ARCHIVES

Blinatumomab Demonstrates High Response Rate in ALL

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

Potti Claimed Rhodes Credential in Bio Submitted for DOD Funding

July 30, 2010

Former BMS Executive Bodnar Indicted.

April 25, 2008

FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”

June 24, 2011

DCPC Advisors Okay New Program Project Grants In Prevention

January 27, 1995

Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products.

October 8, 2004